Zonulin and Intestinal Barrier Integrity in Athletes: Potential Implications of Nutritional Interventions for Health and Performance
DOI:
https://doi.org/10.12775/QS.2026.77.76047Keywords
zonulin, intestinal barrier, athletes, exercise, gastrointestinal health, sports performance, nutritional interventionsAbstract
Objective: This systematic review aimed to synthesize current evidence on the role of zonulin in intestinal barrier integrity and to explore the potential relevance of intestinal barrier function for athlete health, recovery, and physical performance, with particular emphasis on nutritional interventions.
Materials and Methods: A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Embase was conducted to identify studies published between 2000 and 2025 addressing zonulin, intestinal permeability, tight-junction function, gastrointestinal symptoms, exercise, athletes, and nutritional interventions. Forty-one publications were included in the review.
Results: Zonulin is involved in the regulation of paracellular intestinal permeability through modulation of tight-junction integrity. Alterations in intestinal barrier function have been reported in association with exercise and may be influenced by exercise intensity, training load, environmental conditions, and nutritional factors. Dietary strategies and selected nutritional interventions, including low-FODMAP approaches, probiotics, glutamine, polyphenols, and omega-3 fatty acids, have been investigated for their potential to support gastrointestinal function and intestinal barrier integrity. However, evidence remains heterogeneous, and the interpretation of zonulin concentrations is limited by methodological variability and concerns regarding the specificity and validity of commercially available assays.
Conclusions: Intestinal barrier integrity may represent an important component of gastrointestinal health in athletes and may have implications for recovery, well-being, and physical performance. Zonulin has potential as a biomarker of intestinal barrier dysfunction; however, its clinical and sports-related utility remains insufficiently established. Further well-designed studies in athletic populations using standardized methods are needed to clarify the relationship between exercise, intestinal barrier function, nutritional interventions, and performance-related outcomes.
References
1. Ajamian, M., Steer, D., Rosella, G., & Gibson, P. R. (2019). Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS ONE, 14(1), e0210728. https://doi.org/10.1371/journal.pone.0210728
2. Black, C. J., & Ford, A. C. (2020). Global burden of irritable bowel syndrome: Trends, predictions and risk factors. Nature Reviews Gastroenterology & Hepatology, 17(8), 473–486. https://doi.org/10.1038/s41575-020-0286-8
3. Camilleri, M. (2019). Leaky gut: Mechanisms, measurement and clinical implications in humans. Gut, 68(8), 1516–1526. https://doi.org/10.1136/gutjnl-2019-318427
4. Camilleri, M., Lasch, K., & Zhou, W. (2012). Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver Physiology, 303(7), G775–G785. https://doi.org/10.1152/ajpgi.00155.2012
5. Chaiyasut, C., Sivamaruthi, B. S., Lailerd, N., Sirilun, S., Khongtan, S., Fukngoen, P., Peerajan, S., Saelee, M., Chaiyasut, K., Kesika, P., & Sittiprapaporn, P. (2022). Probiotics supplementation improves intestinal permeability, obesity index and metabolic biomarkers in elderly Thai subjects: A randomized controlled trial. Foods, 11(3), 268. https://doi.org/10.3390/foods11030268
6. Drago, S., El Asmar, R., Di Pierro, M., Clemente, M. G., Tripathi, A., Sapone, A., Thakar, M., Iacono, G., Carroccio, A., D'Agate, C., Not, T., Zampini, L., Catassi, C., & Fasano, A. (2006). Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scandinavian Journal of Gastroenterology, 41(4), 408–419. https://doi.org/10.1080/00365520500235334
7. El Asmar, R., Panigrahi, P., Bamford, P., Berti, I., Not, T., Coppa, G. V., Catassi, C., & Fasano, A. (2002). Host-dependent activation of the zonulin system is involved in the impairment of the gut barrier function following bacterial colonization. Gastroenterology, 123(5), 1607–1615. https://doi.org/10.1053/gast.2002.36578
8. Fasano, A. (2011). Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer. Physiological Reviews, 91(1), 151–175. https://doi.org/10.1152/physrev.00003.2008
9. Fasano, A. (2012a). Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications. Clinical Gastroenterology and Hepatology, 10(10), 1096–1100. https://doi.org/10.1016/j.cgh.2012.08.012
10. Fasano, A. (2012b). Zonulin, regulation of tight junctions, and autoimmune diseases. Annals of the New York Academy of Sciences, 1258(1), 25–33. https://doi.org/10.1111/j.1749-6632.2012.06538.x
11. Fasano, A. (2020). All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Research, 9, 69. https://doi.org/10.12688/f1000research.20510.1
12. Fasano, A., Not, T., Wang, W., Uzzau, S., Berti, I., Tommasini, A., & Goldblum, S. E. (2000). Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. The Lancet, 355(9214), 1518–1519. https://doi.org/10.1016/S0140-6736(00)02169-3
13. Galipeau, H. J., & Verdu, E. F. (2016). The complex task of measuring intestinal permeability in basic and clinical science. Neurogastroenterology & Motility, 28(7), 957–965. https://doi.org/10.1111/nmo.12871
14. Gil-Cardoso, K., Ginés, I., Pinent, M., Ardévol, A., Blay, M., & Terra, X. (2016). Effects of flavonoids on intestinal inflammation, barrier integrity and changes in gut microbiota during diet-induced obesity. Nutrition Research Reviews, 29(2), 234–248. https://doi.org/10.1017/S0954422416000159
15. Hałasa, M., Maciejewska, D., Ryterska, K., Baśkiewicz-Hałasa, M., Safranow, K., & Stachowska, E. (2019). Assessing the association of elevated zonulin concentration in stool with increased intestinal permeability in active professional athletes. Medicina, 55(10), 710. https://doi.org/10.3390/medicina55100710
16. Hanning, N., Edwinson, A. L., Ceuleers, H., Peters, S. A., De Man, J. G., Hassett, L. C., De Winter, B. Y., & Grover, M. (2021). Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review. Therapeutic Advances in Gastroenterology, 14, 1756284821993586. https://doi.org/10.1177/1756284821993586
17. Houttu, N., Mokkala, K., & Laitinen, K. (2018). Overweight and obesity status in pregnant women are related to intestinal microbiota and serum metabolic and inflammatory profiles. Clinical Nutrition, 37(6), 1955–1966. https://doi.org/10.1016/j.clnu.2017.12.013
18. Junker, Y., Zeissig, S., Kim, S. J., Barisani, D., Wieser, H., Leffler, D. A., Zevallos, V., Libermann, T. A., Dillon, S., Freitag, T. L., Kelly, C. P., & Schuppan, D. (2012). Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. Journal of Experimental Medicine, 209(13), 2395–2408. https://doi.org/10.1084/jem.20102660
19. Küme, T., Acar, S., Tuhan, H., Çatlı, G., Anık, A., Gürsoy Çalan, Ö., Böber, E., & Abacı, A. (2017). The relationship between serum zonulin level and clinical and laboratory parameters of childhood obesity. Journal of Clinical Research in Pediatric Endocrinology, 9(1), 31–38. https://doi.org/10.4274/jcrpe.3682
20. Lammers, K. M., Lu, R., Brownley, J., Lu, B., Gerard, C., Thomas, K., Rallabhandi, P., Shea-Donohue, T., Tamiz, A., Alkan, S., Netzel-Arnett, S., Antalis, T., Vogel, S. N., & Fasano, A. (2008). Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology, 135(1), 194–204.e3. https://doi.org/10.1053/j.gastro.2008.03.023
21. Lamprecht, M., Bogner, S., Schippinger, G., Steinbauer, K., Fankhauser, F., Hallstroem, S., Schuetz, B., & Greilberger, J. F. (2012). Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. Journal of the International Society of Sports Nutrition, 9(1), 45. https://doi.org/10.1186/1550-2783-9-45
22. Linsalata, M., Ignazzi, A., D'Attoma, B., Riezzo, G., Mallardi, D., Orlando, A., Prospero, L., Notarnicola, M., De Nunzio, V., Pinto, G., & Russo, F. (2024). Relationship between markers of gut barrier function and erythrocyte membrane PUFAs in diarrhea-predominant IBS patients undergoing a low-FODMAP diet. Nutrients, 16(16), 2706. https://doi.org/10.3390/nu16162706
23. Ludvigsson, J. F., Leffler, D. A., Bai, J. C., Biagi, F., Fasano, A., Green, P. H. R., Hadjivassiliou, M., Kaukinen, K., Kelly, C. P., Leonard, J. N., Lundin, K. E. A., Murray, J. A., Sanders, D. S., Walker, M. M., Zingone, F., & Ciacci, C. (2013). The Oslo definitions for coeliac disease and related terms. Gut, 62(1), 43–52. https://doi.org/10.1136/gutjnl-2011-301346
24. Moreno-Navarrete, J. M., Sabater, M., Ortega, F., Ricart, W., & Fernández-Real, J. M. (2012). Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS ONE, 7(5), e37160. https://doi.org/10.1371/journal.pone.0037160
25. Oka, P., Parr, H., Barberio, B., Black, C. J., Savarino, E. V., & Ford, A. C. (2020). Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 5(10), 908–917. https://doi.org/10.1016/S2468-1253(20)30217-X
26. Ohlsson, B., Orho-Melander, M., & Nilsson, P. M. (2017). Higher levels of serum zonulin may rather be associated with increased risk of obesity and hyperlipidemia, than with gastrointestinal symptoms or disease manifestations. International Journal of Molecular Sciences, 18(3), 582. https://doi.org/10.3390/ijms18030582
27. Prospero, L., Riezzo, G., Linsalata, M., Orlando, A., D'Attoma, B., & Russo, F. (2021). Psychological and gastrointestinal symptoms of patients with irritable bowel syndrome undergoing a low-FODMAP diet: The role of the intestinal barrier. Nutrients, 13(7), 2469. https://doi.org/10.3390/nu13072469
28. Scheffler, L., Crane, A., Heyne, H., Tönjes, A., Schleinitz, D., Ihling, C. H., Stumvoll, M., Freire, R., Fiorentino, M., Fasano, A., Kovacs, P., & Heiker, J. T. (2018). Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Frontiers in Endocrinology, 9, 22. https://doi.org/10.3389/fendo.2018.00022
29. Seethaler, B., Basrai, M., Neyrinck, A. M., Nazare, J.-A., Walter, J., Delzenne, N. M., & Bischoff, S. C. (2021). Biomarkers for assessment of intestinal permeability in clinical practice. American Journal of Physiology-Gastrointestinal and Liver Physiology, 321(1), G11–G17. https://doi.org/10.1152/ajpgi.00113.2021
30. Sequeira, I. R., Lentle, R. G., Kruger, M. C., & Hurst, R. D. (2014). Standardising the lactulose mannitol test of gut permeability to minimise error and promote comparability. PLoS ONE, 9(6), e99256. https://doi.org/10.1371/journal.pone.0099256
31. Singh, P., Silvester, J., Chen, X., Xu, H., Sawhney, V., Rangan, V., Iturrino, J., Nee, J., Duerksen, D. R., & Ballou, S. (2019). Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United European Gastroenterology Journal, 7(5), 709–715. https://doi.org/10.1177/2050640619826419
32. Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., Ghoshal, U. C., Simren, M., Tack, J., Whitehead, W. E., Dumitrascu, D. L., Fang, X., Fukudo, S., Kellow, J., Okeke, E., Quigley, E. M. M., Schmulson, M., Whorwell, P., Archampong, T., Adibi, P., Andresen, V., Benninga, M. A., ... Palsson, O. S. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology, 160(1), 99–114.e3. https://doi.org/10.1053/j.gastro.2020.04.014
33. Stenman, L. K., Lehtinen, M. J., Meland, N., Christensen, J. E., Yeung, N., Saarinen, M. T., Courtney, M., Burcelin, R., Lähdeaho, M.-L., Linros, J., Apter, D., Scheinin, M., Kloster Smerud, H., Rissanen, A., & Lahtinen, S. (2016). Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults—Randomized controlled trial. EBioMedicine, 13, 190–200. https://doi.org/10.1016/j.ebiom.2016.10.036
34. Sturgeon, C., & Fasano, A. (2016). Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers, 4(4), e1251384. https://doi.org/10.1080/21688370.2016.1251384
35. Tripathi, A., Lammers, K. M., Goldblum, S., Shea-Donohue, T., Netzel-Arnett, S., Buzza, M. S., Antalis, T. M., Vogel, S. N., Zhao, A., Yang, S., Arrietta, M.-C., Meddings, J. B., & Fasano, A. (2009). Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proceedings of the National Academy of Sciences, 106(39), 16799–16804. https://doi.org/10.1073/pnas.0906773106
36. Troisi, J., Venutolo, G., Terracciano, C., Delli Carri, M., Di Micco, S., Landolfi, A., & Fasano, A. (2021). The therapeutic use of the zonulin inhibitor AT-1001 (larazotide) for a variety of acute and chronic inflammatory diseases. Current Medicinal Chemistry, 28(28), 5788–5807. https://doi.org/10.2174/0929867328666210104110053
37. Vanuytsel, T., Vermeire, S., & Cleynen, I. (2013). The role of haptoglobin and its related protein, zonulin, in inflammatory bowel disease. Tissue Barriers, 1(5), e27321. https://doi.org/10.4161/tisb.27321
38. Vazquez-Roque, M. I., Camilleri, M., Smyrk, T., Murray, J. A., Marietta, E., O'Neill, J., Carlson, P., Lamsam, J., Janzow, D., Eckert, D., Burton, D., & Zinsmeister, A. R. (2013). A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function. Gastroenterology, 144(5), 903–911.e3. https://doi.org/10.1053/j.gastro.2013.01.049
39. Verdu, E. F., Armstrong, D., & Murray, J. A. (2009). Between celiac disease and irritable bowel syndrome: The "no man's land" of gluten sensitivity. American Journal of Gastroenterology, 104(6), 1587–1594. https://doi.org/10.1038/ajg.2009.188
40. Wang, W., Uzzau, S., Goldblum, S. E., & Fasano, A. (2000). Human zonulin, a potential modulator of intestinal tight junctions. Journal of Cell Science, 113(24), 4435–4440. https://doi.org/10.1242/jcs.113.24.4435
41. Zhou, Q., Verne, M. L., Fields, J. Z., Lefante, J. J., Basra, S., Salameh, H., & Verne, G. N. (2019). Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut, 68(6), 996–1002. https://doi.org/10.1136/gutjnl-2017-315136
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Izabela Sieradzka, Anna Zdziebło, Katarzyna Wajda, Justyna Wojnar

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 177
Number of citations: 0